Fumbling, flopping, and floundering.
Take your pick of which word to use, but all of them apply to Illumina Inc. (NASDAQ:ILMN) right now. The genomic-sequencing company’s stock is down around 30% in 2016. Management has missed its forecasts and Wall Street expectations multiple times over the past 12 months. Here’s what Illumina’s management said about the current woes in the company’s third-quarter conference call -- and what they’re planning to do about those problems. (All quotes courtesy of S&P Global Market Intelligence.)
